**Table 2. Global Function Status Outcomes From AChEI Trials**

| **Medication/ Supplement****Class** | **Study** | **Specific condition** | **N randomized** | **Drug (Dosage)** | **Measure** | **Time** | **Intervention Group** | **Control Group** | **p-value** | **Notes and related outcomes** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Donepezil | Doody, 2009105,106 | MCI | IG: 409CG: 412 | 5-10 mg | CGIC-MCI, mean change (SE) | 11m | 3.9 (0.1) | 3.9 (0.1) | NSD | Also report CDR-SB (NSD between groups at 11m) and PGA (p=0.0009 between groups at 11m). |
| Requena, 2004108,109 | AD | IG: 30CG: 18 | 5-10 mg | NR | 12/24m | NA | NA | NA | No global function assessment reported. |
| Rivastigmine | Ballard, 2008115VantagE Study | VaD including probable | IG: 365CG: 345 | 3-12 mg | ADCS-CGIC, mean change (SE) | 6m | 4.0 (1.31) | 4.1 (1.27) | NSD | BL data for ADCS-CGIC NR. Also report GDS, NSD between groups at 6m.  |
| Feldman, 2007116Study 304 | AD | IG1: 227IG2: 229CG: 222 | 2-12 mg | CIBIC+, mean change (SD) | 6m | IG1: 3.9 (1.3)IG2: 4.1 (1.3) | 4.5 (1.3) | IG1: <0.001IG2: <0.05 | Mean change from BL for both IGs also significantly different from CG at 12 and 24m for CIBIC+. Also report GDS, only IG1 is significantly different from CG at 6m (p<0.05). |
| Mok, 2007117 | VaD (subcortical) | IG: 20CG: 20 | 6 mg | NR | 6m | NA | NA | NA | No global function assessment report. |
| Winblad, 2007118-127IDEAL Study | AD including probable | IG1: 293IG2: 303IG3: 297CG: 302 | IG1: 9.5 mg/24 hour patchIG2: 17.4 mg/24 hour patchIG3: 12 mg capsule | ADCS-CGIC, mean change (SD) | 6m | IG1: 3.9 (1.2)IG2: 4.0 (1.3)IG3: 3.9 (1.3) | 4.2 (1.3) | IG1: 0.01IG2: 0.054IG3: 0.009 | BL data for ADCS-CGIC NR. Also report mean change of ADCS-CGIC subscales. |
| Galantamine | Auchus, 2007110GAL-INT-26 Study | VaD | IG: 397CG: 391 | 16-24 mg | CIBIC+ | 6m | NR | NR | NSD | IG showed numerical but not significant improvement on the CIBIC+ than CG (data NR). |
| Rockwood, 2006111-114VISTA | AD (probable) | IG: 64CG: 66 | 16-24 mg | CIBIC+, mean (SD) | BL | 3.4 (0.7) | 3.7 (0.9) | NR | Followup CIBIC+ values estimated from figures, 2m followup also reported. |
| 4m | 3.7 | 4.1 | 0.03 |
| Memantine | Bakchine, 2008128 | AD (probable) | IG: 318CG: 152 | 20 mg | CIBIC+, mean change | 3m | 3.90 | 4.11 | 0.033 | Also report difference between group at each followup point |
| 4m | 3.99 | 4.27 | 0.012 |
| 6m | 4.12 | 4.19 | 0.523 |
| Ferris, 2007129 | MCI | IG: 30CG: 30 | 20 mg | NR | 3m | NR | NR | NR | NSD or trends on any of the learning or memory tests of the Psychologix Computerized Test Battery, on the self-report of memory improvement. P-value was < 0.10 on the CogScreen variable at one or more visits. |
| Porsteinsson, 2008130MEM-MD-12 Study | AD (probable) | IG: 217CG: 216 | 20 mg | CIBIC+, mean (SD) | 6m | 4.38 (1.0) | 4.42 (0.96) | 0.843 | NSD between groups for all visits on the CIBIC+. |

**Abbreviations:** AD = Alzheimer’s disease; ADCS-CGIC = Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change; BL = baseline; CDR = Clinician Dementia Rating Scale; CDR-SB = Clinical Dementia Rating Scale-Summary of Boxes; CG = control group; CGIC-MCI = Clinical Global Impression of Change-Mild Cognitive Impairment; CIBIC+ = Clinician’s Interview-based Impression of Change plus Caregiver Input; GDS = Global Deterioration Scale; IG = intervention group; m = month(s); MCI = mild cognitive impairment; mg = milligram(s); N = number; NR = not reported; NSD = no significant difference; PGA = Patient Global Assessment; SD = standard deviation; SE = standard error; VaD = vascular dementia.